Targeted approaches for treating advanced clear cell renal carcinoma

Onkologie

Volumn 29, Issue 8-9, 2006, Pages 394-402

  Van Spronsen, Dick Johan ^a   De Mulder, Pieter H M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Metastatic systemic therapy; Renal cell carcinoma; Targeted drugs

Indexed keywords

AE 941; ALPHA INTERFERON; BEVACIZUMAB; ERLOTINIB; FLUOROURACIL; GEMCITABINE; INTERLEUKIN 2; LAPATINIB; MONOCLONAL ANTIBODY; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; VASCULOTROPIN; VATALANIB; VON HIPPEL LINDAU PROTEIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; ALOPECIA; ANEMIA; ANGIOGENESIS; ASTHENIA; BLOOD DISEASE; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL TRIAL; DENDRITIC CELL; DIARRHEA; DYSPEPSIA; ENZYME DEFICIENCY; FATIGUE; HAND FOOT SYNDROME; HORMONAL THERAPY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY CARCINOMA; LEUKOPENIA; MUCOSA INFLAMMATION; NAUSEA; NEPHRECTOMY; PROTEINURIA; RASH; REVIEW; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS;

EID: 33748581389     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094250     Document Type: Review

References (114)

1. www.seer.cancer.gov.
2. Flanigan RC, Mickisch G, Sylvester R, Tangen C, van Poppel H, Crawford ED: Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071-6.
3. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966-70.
4. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al.: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655-9.
5. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS: Resection of metastatic renal cell carcinoma. J Clin Oncol 1998;16:2261-6.
6. Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N Engl J Med 1996;335:865-75.
7. Motzer RJ, Russo P: Systemic therapy for renal cell carcinoma. J Urol 2000;163:408-17.
8. Yagoda A, Abi-Rached B, Petrylak D: Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995;22:42-60.
9. Stadler WM, Huo D, George C, Yang X, Ryan CW, Karrison T, et al.: Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol 2003;170:1141-5.
10. Goey SH, Verweij J, Stoter G: Immunotherapy of metastatic renal cell cancer. Ann Oncol 1996;7:887-900.
11. Kaelin WG: Kidney cancer: lessons from von Hippel-Lindau disease. ASCO Annu Meet Proc (Post-Meeting Ed), J Clin Oncol 2004;22(suppl 15):4502.
12. Pyrhonen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, et al.: Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999;17:2859-67.
13. Medical Research Council Renal Cancer Collaborators: Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999;353:14-7.
14. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al.: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-92.
15. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, et al.: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994;271:907-13.
16. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688-96.
17. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, et al.: Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127-32.
18. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, et al.: Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987;316:898-905.
19. Gore ME, Galligioni E, Keen CW, Sorio R, Loriaux EM, Grobben HC, et al.: The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2. Eur J Cancer 1994;30A:329-33.
20. Jones M, Philip T, Palmer P, von der Maase H, Vinke J, Elson P, et al.: The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. Cancer Biother 1993;8:275-88.
21. Sleijfer DT, Janssen RA, Buter J, de Vries EG, Willemse PH, Mulder NH: Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 1992;10:1119-23.
22. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, et al.: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunotherapie. N Engl J Med 1998;338:1272-8.
23. Atzpodien J, Lopez HE, Kirchner H, Bodenstein H, Pfreundschuh M, Rebmann U, et al.: Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 1995;13:497-501.
24. Ravaud A, Negrier S, Cany L, Merrouche Y, Le Guillou M, Blay JY, et al.: Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma. Br J Cancer 1994;69:1111-4.
25. Ilson DH, Motzer RJ, Kradin RL, Vogelzang NJ, Bajorin DF, Scher HI, et al.: A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma. J Clin Oncol 1992;10:1124-30.
26. Vogelzang NJ, Lipton A, Figlin RA: Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol 1993;11:1809-16.
27. Tourani JM, Pfister C, Tubiana N, Ouldkaci M, Prevot G, Lucas V, et al.: Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design - the Subcutaneous Administration Propeukin Program Cooperative Group. J Clin Oncol 2003;21:3987-94.
28. Clark JI, Kuzel TM, Lestingi TM, Fisher SG, Sorokin P, Martone B, et al.: A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population. Ann Oncol 2002;13:606-13.
29. Verra N, Jansen R, Groenewegen G, Mallo H, Kersten MJ, Bex A, et al.: Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma. Br J Cancer 2003;88:1346-51.
30. Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, de Vries IJ, Jongmans W, Adema GJ, et al.: Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. J Immunother 2002;25:500-8.
31. Holtl L, Zelle-Rieser C, Gander H, Papesh C, Ramoner R, Bartsch G, et al.: Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 2002;8:3369-76.
32. Marten A, Flieger D, Renoth S, Weineck S, Albers P, Compes M, et al.: Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol Immunother 2002;51:637-44.
33. Marten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U, et al.: Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 2003;14:483-94.
34. Avigan D, Vasir B, Gong J, Borges V, Wu Z, Uhl L, et al.: Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 2004;10:4699-708.
35. Avigan D: Dendritic cell-tumor fusion vaccines for renal cell carcinoma. Clin Cancer Res 2004;10:6347S-52S.
36. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, et al.: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000;343:750-8.
37. Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ: Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 2002;20:2017-24.
38. Pedrazzoli P, Da Prada GA, Giorgiani G, Schiavo R, Zambelli A, Giraldi E, et al.: Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer 2002;94:2409-15.
39. Bregni M, Dodero A, Peccatori J, Pescarollo A, Bernardi M, Sassi I, et al.: Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002;99:4234-6.
40. Hentschke P, Barkholt L, Uzunel M, Mattsson J, Wersall P, Pisa P et al.: Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 2003;31:253-61.
41. Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR, et al.: Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003;102:3829-36.
42. Takahashi Y, Childs RW: Nonmyeloablative transplantation: an allogeneic-based immunotherapy for renal cell carcinoma. Clin Cancer Res 2004;10:6353S-9S.
43. Schaap N, Schattenberg A, Bar B, Preijers F, van de Wiel-van Kemenade E, de Witte T: Induction of graft-versus-leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by pre-emptive donor leukocyte infusions. Leukemia 2001;15:1339-46.
44. Steffens MG, Boerman OC, de Mulder PH, Oyen WJ, Buijs WC, Witjes JA, et al.: Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 1999;5:3268Ss-74S.
45. Brouwers AH, Buijs WC, Oosterwijk E, Boerman OC, Mala C, de Mulder PH, et al.: Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison. Clin.Cancer Res. 2003;9:3953S-60S.
46. Varga Z, de Mulder PH, Kruit W, Hegele A, Hofmann R, Lamers C, et al.: A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients. Folia Biol (Praha) 2003;49:74-7.
47. Bleumer I, Knuth A, Oosterwijk E, Hofmann R, Varga Z, Lamers C, et al.: A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 2004;90:985-90.
48. Trikha M, Corringham R, Klein B, Rossi JF: Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003;9:4653-65.
49. Negrier S, Perol D, Menetrier-Caux C, Escudier B, Pallardy M, Ravaud A, et al.: Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6 - from the Groupe Francais d'Immunotherapie. J Clin Oncol 2004;22:2371-8.
50. Blay JY, Rossi IF, Wijdenes J, Menetrier-Caux C, Schemann S, Negrier S, et al.: Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 1997;72:424-30.
51. Klinkhoff A: Biological agents for rheumatoid arthritis: targeting both physical function and structural damage. Drugs 2004;64:1267-83.
52. Maisey NR, Hall K, Lee C, Timotheadou E, Ahern R, Eisen T, Gore M: Infliximab: a phase II trial of the tumour necrosis factor (TNFa) monoclonal antibody in patients with advanced renal cell cancer (RCC). ASCO Annu Meet Proc (Post-Meeting Ed), J Clin Oncol 2004;22(suppl 15): 4514.
53. Srivastava PK: Immunotherapy for human cancer using heat shock protein-peptide complexes. Curr Oncol Rep 2005;7:104-8.
54. Wood CG, Escudier B, Gorelov S, Krajka K, Lacombe L, Fossa S, Hoos A, Flanigan R, Figlin R, Srivastava P: A multicenter randomized study of adjuvant heat-shock protein peptide-complex 96 (HSPPC-96) vaccine in patients with high-risk of recurrence after nephrectomy for renal cell carcinoma (RCC) - a preliminary report. ASCO Annu Meet Proc (Post-Meeting Ed), J Clin Oncol 2004;22:2618.
55. Rini BI, Small EJ: Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005;23:1028-43.
56. Gnarra JR, Zhou S, Merrill MJ, Wagner JR, Krumm A, Papavassiliou E, et al.: Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U.S.A. 1996;93:10589-94.
57. Turner KJ, Moore JW, Jones A, Taylor CF, Cuthbert-Heavens D, Han C, et al.: Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 2002;62:2957-61.
58. Wiesener MS, Munchenhagen PM, Berger I, Morgan NV, Roigas J, Schwiertz A, et al.: Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1 alpha in clear cell renal carcinomas. Cancer Res 2001;61:5215-22.
59. Massfelder T, Lang H, Schordan E, Lindner V, Rothhut S, Welsch S, et al.: Parathyroid hormone-related protein is an essential growth factor for human clear cell renal carcinoma and a target for the von Hippel-Lindau tumor suppressor gene. Cancer Res 2004;64:180-8.
60. Grabmaier K, Weijert MC Ad, Verhaegh GW, Schalken JA, Oosterwijk E: Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene 2004;23:5624-31.
61. Na X, Wu G, Ryan CK, Schoen SR, di'Santagnese PA, Messing EM: Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol 2003;170:588-92.
62. Rini BI, Small, EJ: Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005;23:1028-43.
63. Knebelmann B, Ananth S, Cohen HT, Sukhatme VP: Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Cancer Res 1998;58:226-31.
64. Sargent ER, Gomella LG, Belldegrun A, Linehan WM, Kasid A: Epidermal growth factor receptor gene expression in normal human kidney and renal cell carcinoma. J Urol 1989;142:1364-8.
65. Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-80.
66. Scappaticci FA: Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002;20:3906-27.
67. Amato RJ: Thalidomide therapy for renal cell carcinoma. Crit Rev Oncol Hematol 2003;46(suppl):S59-S65.
68. Eisen T: Phase II results of a phase II/III study comparing thalidomide with medroxyprogesterone in patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 2003;22:400(abstr 1606).
69. Amato RJ, Schell J, Thompson N, Moore R, Miles B: Phase II study of thalidomide + interleukin-2 (il-2) in patients with metastatic renal cell carcinoma (MRCC). ASCO Annu Meet Proc 2003; 1556.
70. Sella A, Sternberg C, Yarom N, Sava T, Calabry F, Zisman A, Lindner A, Cetta GL: Phase II study of low dose thalidomide and interferon-alfa in metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 2003;22:402(abstr 1614).
71. Gordon MS, Manola J, Fairclough D, Cella D, Richardson R, Sosman J, Kasimis B, Dutcher JP, Wilding G: Low dose interferon-á2b (IFN) + thalidomide (T) in patients (pts) with previously untreated renal cell cancer (RCC). Improvement in progression-free survival (PFS) but not quality of life (QoL) or overall survival (OS). A phase III study of the Eastern Cooperative Oncology Group (E2898). ASCO Annu Meet Proc (Post-Meeting Ed), J Clin Oncol 2004;22 (suppl 15):4516.
72. Batist G, Patenaude F, Champagne P, Croteau D, Levinton C, Hariton C, et al.: Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann Oncol 2002;13:1259-63.
73. Batist G, Champagne P, Hariton C, Dupont E: Dose-survival relationship in a phase II study of neovastat in refractory renal cell carcinoma patients. Proc Am Soc Clin Oncol 2002;abstr 1907.
74. Escudier B, Venner P, Buckowski R, Szczylik C, Oudard S, Champagne P, Hariton C, Dupont E: Phase III trial of Neovastat in metastatic renal cell carcinoma patients refractory to immunotherapy. ASCO Annu Meet Proc 2003;844.
75. Escudier B, Venner P, Stern L, Donovan M, Croteau D, Champagne P, Bukowski R: Prognostic factors in metastatic renal cell carcinoma after failure of immunotherapy: lessons from a large phase III trial. ASCO Annu Meet Proc (Post-Meeting Ed), J Clin Oncol 2004;22(suppl 15):4547.
76. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
77. Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL. Cancer and Leukemia Group B 90206: a randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 2004;10:2584-6.
78. Sistla A, Sunga A, Phung K, Koparkar A, Shenoy N: Powder-in-bottle formulation of SU011248. Enabling rapid progression into human clinical trials. Drug Dev Ind Pharm 2004;30:19-25.
79. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al.: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
80. Sun L, Liang C, Shirazian S, Zhou Y, Miller T, Cui J, et al.: Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl) amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003;46:1116-9.
81. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, et al.: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-605.
82. Motzer RJ, Rini BI Michaelson MD, et al.: Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). J Clin Oncol 2005;23:16S (abstr 4508).
83. Motzer RJ, Rini BI, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Zhu J, Kim ST, Baum C: SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial. ASCO Annu Meet Proc (Post-Meeting Ed), J Clin Oncol 2004; 22(suppl 15):4500.
84. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, et al.: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178-89.
85. George D, Michaelson D, Oh WK, Reitsma D, Laurent D, Mietlowski W, Wang Y, Dugan M, Kaelin WG, Kantoff P: Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 2003;22:385(abstr 1548).
86. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, et al.: Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003;17:590-603.
87. Higa GM: Targeted therapies in oncology: in the crosshairs or at the crossroads? Expert Rev Anticancer Ther 2004;4:61-75.
88. Takai Y, Sasaki T, Matozaki T: Small GTP-binding proteins. Physiol Rev 2001;81:153-208.
89. Avruch J, Khokhlatchev A, Kyriakis JM, Luo Z, Tzivion G, Vavvas D, et al.: Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res 2001;56:127-55.
90. Bollag G, Freeman S, Lyons JF, Post LE: Raf pathway inhibitors in oncology. Curr Opin Investig Drugs 2003;4:1436-41.
91. Wilhelm S, Chien DS: BAY 43-9006: preclinical data. Curr Pharm Des 2002;8:2255-7.
92. Strumberg D, Voliotis D, Moeller JG, Hilger RA, Richly H, Kredtke S, et al.: Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther 2002;40:580-1.
93. Ahmad T, Eisen T: Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004;10:6388S-92S.
94. Ratain MJ, Flaherty KT, Stadler WM, O'Dwyer P, Kaye S, Xiong H, Patnaik A, Gore M, Lee RJ, Eisen T: Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). ASCO Annu Meet Proc (Post-Meeting Ed), J Clin Oncol 2004;22(suppl 15):4500.
95. Escudier B, Szczylik C Eisen T, et al.: Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2005;23:16S(abstr 4510).
96. Dutcher JP: Mammalian target of rapamycin inhibition. Clin Cancer Res 2004;10:6382S-7S.
97. Chan S: Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 2004;91:1420-4.
98. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, et al.: Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22:7004-14.
99. Panwalkar A, Verstovsek S, Giles FJ: Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 2004;100:657-66.
100. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, et al.: Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004;22:2336-47.
101. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, et al.: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909-18.
102. Hidalgo M, Atkins MB, Stadler WM, Logan T, Dutcher JP, Hudes G, Mashall B, Liou SH, Dukart G: A randomized double-blind phase 2 study of intravenous (IV) CCI-779 administered weekly to patients with advanced renal cell carcinoma (RCC: prognostic factor analysis. Proc Am Soc Clin Oncol 2003;22:201(abstr 804).
103. Atkins MB, Hidalgo M, Stadler W, Logan T, Dutcher JP, Hudes G: A randomized double-blind phase 2 study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol 2002;abstr 36.
104. Dutcher JP, Hudes G, Motzer R, KO YJ, Smith JW, Zonno K, Marshall B, Dukart G, Liou SH: Preliminary report of a phase 1 study of intravenous (iv) CCI-779 given in combination with interferon-a (IFN) to patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 2003;22:213(abstr 854).
105. Smith JW, Ko YJ, Dutcher J, Hudes G, Escudier B, Motzer R, Négrier S, Duclos B, Galand L, Strauss L: Update of a phase 1 study of intravenous CCI-779 given in combination with interferon-a to patients with advanced renal cell carcinoma. ASCO Annu Meet Proc (Post-Meeting Ed), J Clin Oncol 2004;22(suppl 15):4513.
106. Motzer RJ, Amato R, Todd M, Hwu WJ, Cohen R, Baselga J, et al.: Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 2003;21:99-101.
107. Schwartz G, Dutcher JP, Vogelzang NJ, Gollog J, Thompson J, Bukowski RM, Figlin RA, Lohner M, Roskos L, Hwang CC, Foon KA, Schwab G, Rowinsky EK: Phase 2 clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer (RCC). ASCO Annu Meet Proc, J Clin Oncol 2002;91.
108. Drucker B, Bacik J, Ginsberg M, Marion S, Russo P Mazumdar M, et al.: Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Invest New Drugs 2003;21:341-5.
109. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, et al.: A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004;64:6652-9.
110. Burris HA 3rd: Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 2004;9:10-5(suppl 3).
111. Hainsworth JD, Sosman JA, Spigel DR, Schwert RC, Carrell DL, Hubbard F, Greco FA: Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC). ASCO Annu Meet Proc (Post-Meeting Ed), J Clin Oncol 2004;22(suppl 15):4502.
112. Spigel DR, Hainsworth JD, Sosman JA, et al.: Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): update of a phase II multicenter trial. J Clin Oncol 2005;23:16S(abstr 4540).
113. Parulekar WR, Eisenhauer EA: Novel endpoints and design of early clinical trials. Ann Oncol 2002;13:139-43(suppl 4).
114. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al.: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004;22:777-84.